Neha Patil (Editor)

Opsona Therapeutics

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Website
  
www.opsona.com

Founded
  
2004

Opsona Therapeutics wwwopsonacomfiles2008images20081022035742op

Headquarters
  
Dublin, Republic of Ireland

Mark heffernan opsona therapeutics ltd profile


Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.

Based in Ireland, Opsona is a spin-out from Trinity College Dublin (TCD). Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.

Opsona's research is primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

  • Professor Luke A. J. O'Neill
  • Professor Kingston Mills
  • Professor Dermot P. Kelleher

    • Opsona's main investors are international and life-science focused:

  • Inventages Venture Capital (Bahamas)
  • Seroba Bioventures (Ireland)
  • GenenFund (United States)
  • Enterprise Ireland (Ireland)

    • References

    Opsona Therapeutics Wikipedia
    (Text) CC BY-SA